In line with these findings, it is not surprising that a DNA vaccine and FK506 as an adjuvant could be therapeutically effective against APS, an autoimmune disease with a distinct autoantigen, “β2-GPI” [3]. Here, APOH is linked to autoimmune polyendocrinopathy.